cyrilzakka/clinical-trials huggingface dataset:
Endothelial Progenitor Cells

Vascular stenosis as a result of neointimal hyperplasia is a major clinical problem that has an impact on multiple and diverse disciplines, including cardiology (coronary restenosis), cardiothoracic and vascular surgery (saphenous vein and polytetrafluoroethylene \[PTFE\] graft failure), neurology (carotid stenosis), nephrology (dialysis access dysfunction), and transplant medicine (chronic allograft rejection in hearts and kidneys). \[1\] In marked contrast to the deleterious effects of smooth muscle progenitor cells on neointimal hyperplasia, circulating endothelial progenitor cells (EPCs) are believed to play an important role in vascular repair and in the inhibition of neointimal hyperplasia. \[2\] Endothelial progenitor cells (EPCs) circulate in adult peripheral blood and contribute to neovascularization. Satoshi et al. have demonstrated that lineage-committed EPCs and CD34-positive mononuclear cells, their putative precursors, are mobilized during an acute ischemic event in humans. \[3\] Reduced levels of circulating EPCs independently predict atherosclerotic disease progression, thus supporting an important role for endogenous vascular repair to modulate the clinical course of coronary artery disease. \[4\] These observations prompt the hypothesis that circulating EPCs may provide an endogenous repair mechanism to counteract surgery-induced endothelial cell injury and to replace dysfunctional endothelium perioperatively. Therefore, the investigators examined whether levels of circulating EPCs correlate with time course and outcomes of coronary artery bypass surgery to establish a clinical role of endogenous endothelial repair mediated by circulating EPCs.


Eligibility Criteria:
Inclusion Criteria:

* age from 18 to 85 years
* signed written informed consent
* angiographically documented coronary artery disease and indicated for coronary artery bypass surgery

Exclusion Criteria:

* clinical or biochemical evidence for the presence of concomitant inflammatory disease
* chronic renal insufficiency (serum creatinine \> 1.4 mmol/L)
* impaired left ventricular ejection fraction (\< 45%)
* autoimmune or malignant disease
* thrombocytopenia (\< 100 000/L)
* anemia (hemoglobin \< 8.5 g/dL)
* inability to understand the consent form
* previous coronary bypass surgery
* severe peripheral arterial occlusive disease or atrial fibrillation
Photodynamic Therapy (PDT) for Oral Disinfection

Photodynamic therapy (PDT) is a technique used for the oral disinfection. In dentistry, PDT for microbial inactivation may reduces both dental plaque and risk of developing caries as well as contributes to treat gingivitis, periodontitis, peri-implantitis and endodontic diseases. The investigators hypothesis was that PDT with blue light and curcumin promotes oral disinfection during 2 hours after treatment.

PDT uses a non-toxic drug that is activated by exposure to light in the presence of oxygen. The excited state this drug transfers energy or electrons to ground state molecular oxygen producing cytotoxic effects on cell. There are productions of reactive oxygen species (ROS) and disrupts several of the cell's functions. This results in bacterial disinfection. In order to perform the PDT on the oral cavity, a device based on blue LED with transparent acrylic diffuser tip and cylindrical shape was developed.

Eligibility Criteria:
Inclusion Criteria:

* non-users of any antibiotic therapy
* those who do not perform any oral hygiene, such as flossing, brushing and antiseptic mouthwash
* those who performed 12-hour fasting prior the treatment and measurements

Exclusion Criteria:

* oral cancer
* smoking habits
* pregnancy
* patients with partial or total dentures
* orthodontic brackets users
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC

Prognostic impact of AR vs NAR

Whether anatomical is better than non anatomical resection for HCC is still debated. This prospective randomized study aimed to address which approach is better in terms of patients prognosis.

Eligibility Criteria:
Inclusion Criteria:

* patient affected by single HCC
* patients in whom liver resection is indicated
* HCC without vascular invasion and/or thrombosis

Exclusion Criteria:

* multinodular HCC
* metastatic disease
* spontaneous tumor rupture
Characterization of Cardiac Hemodynamics During MultiSite Pacing

The purpose of this study is to evaluate the effects of MultiPoint Pacing (MPP) on cardiac hemodynamics assessed by pressure-volume loop during MPP at implant. NYHA functional class assessment and echocardiographic measurements are performed at 3 months and 12 months post-implant to characterize long-term effect of MPP.


Eligibility Criteria:
Inclusion Criteria:

* Be scheduled to undergo implant of a St Jude Medical CRT-D system with approved standard indication by ESC/EHRA Guidelines
* Be in sinus rhythm at the time of enrollment
* Have the ability to provide informed consent for study participation and be willing and able to comply with the Clinical Investigation Plan (CIP) described evaluations and follow-up schedule

Exclusion Criteria:

* Exhibit Cheyne-Stokes respiration
* Have persistent or permanent atrial fibrillation
* Have complete heart block
* Be in NYHA IV functional class
* Have a recent myocardial infarction within 40 days prior to enrollment
* Have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures in the following 7 months
* Have had a recent CVA or TIA within 3 months prior to enrollment
* Have had intravenous inotropic support in the last 30 days
* Be less than 18 years of age
* Be pregnant
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS.

The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years.

Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers.

Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.


Eligibility Criteria:
Inclusion Criteria:

* Turner syndrome verified by karyotyping

Exclusion Criteria:

* untreated hypothyroidism or hyperthyroidism
* present or past malignant diseases
* clinical liver disease
* treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)
Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.

The purpose of this study is to determine the maximum tolerated dose and safety of S-1 plus radiotherapy for patients with rectal cancer

This stage I study is designed to evaluate the appropriate dose of S-1 plus radiotherapy for patients with R0 resection of rectal cancer for stage II-III patients(AJCC 7th). To evaluate safety, data on adverse events will be collected from the time of enrollment until withdrawn of complete whole study.

Eligibility Criteria:
Inclusion Criteria:

* R0 resection of histologically proved stage II/III rectal cancer;
* 18-75 years old;
* No previous radiotherapy or chemotherapy for rectal cancer;
* Performance status of ECOG 0,1;
* Adequate organ function defined as below:

  i. WBC ≥ 4,000/mm\^3 ii. ANC ≥ 1,500/mm\^3 iii. Hemoglobin ≥ 10g/dL iv. Platelet ≥ 100,000/m\^3 v. Total bilirubin ≤ 1.5ULN vi. AST/ALT ≤ 1.5ULN vii. Serum creatinine ≤ 1.5ULN or creatinine clearance rate ≥ 60ml/min、Urea nitrogen ≤ 1.5ULN viii. Protein in urine dipstick test\<1+; if the test result \>1+ ,total protein in urea must \<500mg within 24 hours
* Able to receive oral administration
* Informed consent

Exclusion Criteria:

* Hypersensitive to S-1 or its excipients
* Pulmonary fibrosis or interstitial pneumonitis found within 28 days prior to registration
* Significant co-morbid medical conditions, including, but not limited to, heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes
* Received any investigational drug or anti-cancer agent
* Pregnant or lactating female or pregnancy test positive
* Severe mental disorder
* Judged ineligible by physicians for participation in the study due to safety concern.
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

This is a study of amifostine to determine how effective it is in the reduction of infection in a high dose chemotherapy regimen with autologous stem cell rescue in children with high risk, relapsed or refractory pediatric solid tumors.

Autologous stem cell transplant (ASCT) permits chemotherapy dose-escalation to exploit the steep dose-response of solid tumors to alkylating agents. Although ASCT regimens have activity in some high risk pediatric solid tumors, non-hematological regimen-related morbidity and mortality are major barriers to additional dose escalation. We hypothesized that the chemoprotectant amifostine (Ethyol®) would reduce the toxicity of ASCT without compromising anti-tumor efficacy. This is a study of amifostine at 1125 mg/m2 to determine the efficacy of it's chemoprotection in the reduction of bacteremia in a high dose busulfan, melphalan and thiotepa chemotherapy regimen with autologous stem cell rescue in children with high risk, relapsed or refractory pediatric solid tumors.

Eligibility Criteria:
Inclusion Criteria:

* High risk Ewing's Sarcoma Family Tumors (ESFT) including Ewing's Sarcoma, Askin's tumor, peripheral PNET
* High risk desmoplastic small round cell tumors (DSRCT)
* Relapsed Wilm's tumor, diffuse anaplastic Wilm's tumor
* High risk brain tumors including PNET/Medulloblastomas/germinomas
* Relapsed germ cell tumors
* Metastatic or relapsed rhabdoid tumors
* Other relapsed/refractory pediatric embryonal tumors
* Less than 30 years of age
* Performance \>= 50%
* Cancer Diagnosis verification and staging
* Disease Response and Recovery
* Adequate Organ Function (Renal, Liver, Cardiac)

Exclusion Criteria:

* Uncontrolled Infection
* Pregnancy or Breastfeeding (For Females)
* Disease Progression
* Uncontrolled Intercurrent Illness
* HIV Positive
* Receiving other Investigational Agents
* Amifostine Allergy
Tele-rehabilitation in Women With Diastasis Recti Abdominis

The aim of this randomized controlled study is to determine the effect of motor-control based telerehabilitation exercise program on inter-recti distance, abdominal endurance, pelvic floor dysfunction, and body-image perception in women with diastasis recti abdominis.

Researchers will compare the effects of motor-control-based telerehabilitation exercise program and conventional exercise programs in women with DRA.

Diastasis of recti abdominis (DRA) is defined as a separation of the two rectus abdominis muscles along the linea alba. Increased volume in the abdominal cavity, hormonal changes during pregnancy, neurodevelopmental differences, or abdominal wall laxity may caused. It is very common during pregnancy and may continue in the postnatal period. The loss of abdominal wall stability and weakened pelvic floor muscles may occur with DRA. The abdominal wall is one of the key point for body posture, trunk and pelvic stability. The core stability exercises, pelvic floor training and trunk muscle trainings are some of the exercise regimes options for management of DRA. However, in our best knowledge, there is no study in the literature that evaluates the effect of motor-control based telerehabilitation exercise program in women with DRA.

Eligibility Criteria:
Inclusion Criteria:

* Post- partum women (min 1 - max 5 years)

Exclusion Criteria:

* Having a neurological, orthopedical or any other condition which affect postural stability.
Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:

1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?

Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

This will be a single-arm, crossover study, in which each patient is their own historical control using a 2:1 conversion ratio of Daxxify to Botox units. Study participants will be selected through the electronic medical records of ophthalmologists at Montefiore Medical Center. Medical documentation on each patient will include information on age, sex, race, Benign Essential Blepharospasm (BEB) diagnosis year and duration, Hemifacial Spasms (HFS) diagnosis year and duration, and past treatments.

The immediate effects (desired or undesired) of Daxxify observed within 48-72 hours, will be defined as (1) complete relief of spasms (2) partial relief to a tolerable level (3) mild to moderate ocular irritation (4) ptosis.

Overall efficacy will be evaluated using the base to peak efficacy (recorded in changes to Jankovic Rating Scale (JRS) scores) and be defined as (1) excellent (resolution of signs and symptoms, only requiring injections \> 5-6 months (2) moderate (improvement in signs and symptoms but requiring repeated injections within \< 5 months (3) poor (no improvement in signs and symptoms).

Adverse side effects will be documented, and Daxxify will be discontinued in any patients who develop significant side effects that outweigh the benefits.

Eligibility Criteria:
Inclusion Criteria:

* Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an ophthalmologist.
* No known neurologic or neuromuscular systematic medications.
* No history or surgical intervention for BEB or HFS.

Exclusion Criteria:

* Patients will be excluded if age \< 18, are pregnant, non-willing, or with contra-indications to botulinum toxin.
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer

To investigate whether pancreatic cancer is the cause of heterotopic ossification of abdominal incision.

Heterotopic ossification of abdominal incision (HOAI) has long been regarded as a rare complication after general surgery. However,according to our retrospective analysis. HOAI was more frequently observed in the malignancy group (33/121 cases, 27.3%) than in the non- malignancy group. Because of the many biases in the retrospective analysis, the result was not widely shared.

The purpose of this prospective study is to confirm that pancreatic cancer is the cause of heterotopic ossification of abdominal incisions. According to postoperative pathology, the patients were divided into two groups: pancreatic cancer group and benign diseases group.The researchers will observe whether patients develop heterotopic ossification of the abdominal incision one year after surgery to conclude.

Eligibility Criteria:
Inclusion Criteria:

* Obtain informed consent from the patients.
* The patient's abdominal incision was double-closed with continuous suture of linea alba and fascia with absorbable suture, and skin was sutured with skin staples.

Exclusion Criteria:

* Refusing to join the study
* Previous history of malignant tumor
* Previous history of midabdominal incision
* Abnormal calcium and phosphorus metabolism
* Distant metastasis
* Palliative operation
* performing neoadjuvant chemotherapy
A Study of Flt3-Ligand Levels in Sjögrens Syndrome

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Eligibility Criteria:
Inclusion Criteria:

* fulfill the ACR-criteria for primary Sjogrens syndrome,
* age above 18 years old

Exclusion Criteria:

* other CNS-disease
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune checkpoint blockade (ICB) and asparaginase.

This study is being conducted to investigate the synergistic effect of combining asparaginase with immune checkpoint blockade (ICB) in tumor-bearing mice. Findings indicate that asparaginase enhances CD8+ T cell activation, and previous reports have shown that nasopharyngeal carcinoma (NPC) patients exhibit a lower response rate to ICB treatment. This study aims to determine whether the combination therapy of asparaginase and ICB is more effective or less effective compared to the standard ICB-only approach for patients with locoregionally advanced (LA-NPC) or recurrent-metastatic NPC (RM-NPC). Participants are being enrolled who have previously received ICB but continue to experience disease progression.

Eligibility Criteria:
Inclusion Criteria: Patients who have previously received immune checkpoint blockade therapy but are still experiencing disease progression -

Exclusion Criteria: Active autoimmune disease

-
Ramosetron OD Tablet and Postdischarge Nausea and Vomiting

Postoperative nausea and vomiting after general anesthesia is one of the common anesthetic complications. If the patient is discharged from the hospital after surgery, proper treatment may be delayed or impossible if nausea and vomiting occurred. Thus, it is necessary to prevent these symptoms beforehand. Patients who underwent day-surgery will be treated with prophylactic ramosetron orally disintegrating tablets to determine whether the frequency of nausea and vomiting is decreased when the patient returned home after discharge.


Eligibility Criteria:
Inclusion Criteria:

* Patients who undergo day-surgery under general anesthesia and are discharged on the day of surgery

Exclusion Criteria:

* Pregnancy or breastfeeding
* Patients who are taking other serotonin receptor antagonists
* Patients who have galactose intolerance or Lapp lactase deficiency
* patients who have glucose-galactose malabsorption
Evaluation of Esthetics Around Immediate Implants in VIP - CT Grafted vs Non-grafted Sites.RCT

An array of soft tissue augmentation techniques have been employed concomitant to implant placement, as free connective tissue grafts or pedicle grafts for keratinized tissue thickening in attempt not only to augment the soft tissue for better resistance to inflammation and improved esthetic stability, but to preserve buccal bone thickness as well.

Results obtained from the literature were controversial regarding the need of soft tissue augmentation to curb buccal bone resorption and preserve pink esthetics. Scarce literature was found, that monitored the ridge alterations following implant placement.

Our study will monitor the effect of soft tissue augmentation on soft tissue esthetics and buccal bone resorption during the process of remodeling in a measurable way.

Alveolar bone remodeling following extraction could not be prevented by immediate implant placement. Soft tissue augmentaion techniques have been suggested in order to overcome the alterations of buccal bone during remodeling. Nevertheless, it is still inconclusive whether soft tissue augmentation procedures actually have a protective role in preserving buccal bone thickness in immediate implants.

Aim is to clinically and radiographically assess the effect of soft tissue grafting on buccal bone resorption and pink esthetics around immediately placed implants in maxillary anterior teeth after 24 months following implant placement. 18 non-restorable maxillary anterior teeth randomly assigned into 2 groups: (test group) immediately placed implants with simultaneous vascular interpositional periosteal connective tissue (VIP-CT) grafting versus non-augmented implant sites (control group). Buccal bone changes were assessed at implant placement (0) and at 4,9,12 and 24 months from baseline by specially manufactured device and at 24 months by cone beam computed tomography scans (CBCT). Pink esthetic score (PES) was evaluated at 6, 9, 12 and 24 months intervals. Pain and satisfaction were assessed through questionnaires to the patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have at least one unrestorable tooth in the esthetic zone that needs to be extracted.
* Patients with healthy systemic condition.
* Buccal bone thickness should be at least 1mm.
* Availability of bone apical and palatal to the socket to provide primary stability.
* Good oral hygiene.

Exclusion Criteria:

* Patients with signs of acute infection related to the area of interest.
* Current and former smokers
* Pregnant.
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of chronic plaque-type
* Patient with 2-10% BSA
* Physician Global Assessment of 2 or greater
* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion Criteria:

* ˂2 or \>10% BSA
* PGA \<2
* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks